Atezolizumab,Carboplatin,Etoposide,Tiragolumab
Roche
['skyscraper-02', 'lung', 'atezo', 'tiragolumab', 'sclc', 'prime']
#asco22 lung oral session skyscraper-02 study tiragolumab (tigit) + atezo + plt doublet chemo v chemo+ atezo:
- no benefit in pfs - no benefit in interim os - no new safety signals unf it looks unlikely that tigit is going to make it to primetime in sclc 
Thoracic Oncologist focused on immunotherapy for lung cancer & immune toxicity. Beaumont RCSI Cancer Centre Dublin; Adjunct Asst Prof Johns Hopkins University